Nathalie Dubois-Stringfellow, Ph.D., serves as Sangamo's, Chief Development Officer and is responsible for overseeing the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease. She has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious and genetic diseases. Dr. Dubois-Stringfellow joined Sangamo in January 2011 as Senior Director, Project Management and later served as our Vice President, Product Development and Management from January 2016 to September 2019 and as our Senior Vice President, Product Development and Management from September 2019 to August 2022. Prior to joining Sangamo, she held various positions in Discovery Research, Preclinical Research, Project Management, Clinical Development and Portfolio Management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc. and most recently XOMA LLC, where she served as Senior Director, Preclinical Portfolio and Alliance Management.
Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in Genetics and Immunology and her Ph.D. in Human Genetics from the Université Pierre et Marie Curie in Paris, France.
What is Nathalie Dubois-Stringfellow's net worth?
The estimated net worth of Nathalie Dubois-Stringfellow is at least $24.62 thousand as of April 21st, 2026. Dr. Dubois-Stringfellow owns 332,769 shares of Sangamo Therapeutics stock worth more than $24,625 as of September 29th. This net worth approximation does not reflect any other investments that Dr. Dubois-Stringfellow may own. Learn More about Nathalie Dubois-Stringfellow's net worth.
How do I contact Nathalie Dubois-Stringfellow?
Has Nathalie Dubois-Stringfellow been buying or selling shares of Sangamo Therapeutics?
Nathalie Dubois-Stringfellow has not been actively trading shares of Sangamo Therapeutics during the past quarter. Most recently, Nathalie Dubois-Stringfellow sold 345,942 shares of the business's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $0.26, for a transaction totalling $89,944.92. Following the completion of the sale, the senior vice president now directly owns 332,769 shares of the company's stock, valued at $86,519.94. Learn More on Nathalie Dubois-Stringfellow's trading history.
Are insiders buying or selling shares of Sangamo Therapeutics?
In the last year, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 415,769 shares worth more than $107,401.67. The most recent insider tranaction occured on April, 22nd when insider Gregory D Davis sold 69,827 shares worth more than $17,456.75. Insiders at Sangamo Therapeutics own 4.1% of the company.
Learn More about insider trades at Sangamo Therapeutics. Information on this page was last updated on 4/22/2026.
